Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials
January 06, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals to Participate In Two Upcoming Investor Conferences
November 12, 2020 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Update
November 09, 2020 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Announced topline data from the Phase 1 monotherapy dose escalation trial of ZN-c5, its investigational oral SERD, in patients with ER+/HER2- advanced breast cancer; Phase 2 trial expected to initiate...
Zentalis Pharmaceuticals to Host a Key Opinion Leader Virtual Meeting to Discuss its Investigational WEE1 Inhibitor ZN-c3 and its Potential as a Best-in-Class Treatment for Advanced Solid Tumors
September 11, 2020 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
September 10, 2020 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Appoints Alexis Pinto as Chief Legal Officer
September 01, 2020 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Update
August 13, 2020 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Closed initial public offering (IPO) of common stock, raising gross proceeds of ~$190.0 millionRaised an additional ~$144.4 million in gross proceeds from recent follow-on offeringCompleted a $20.0...
Zentalis Pharmaceuticals Announces Pricing of Upsized Offering of Common Stock
July 29, 2020 21:11 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock
July 27, 2020 16:19 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Enters into Clinical Collaboration with Eli Lilly and Company to Evaluate its Oral SERD ZN-c5 in Combination with Abemaciclib, a CDK4 and 6 Inhibitor
July 27, 2020 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK & SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...